• SIGN IN
  • GET HELP
  •  

    Home Study Details


    Program Type

    Home Study Webcast

    Credits

    1 Contact Hour(s)

    Release Date

    Wednesday, October 4, 2017

    Offline Date

    Tuesday, April 3, 2018

    ACPE Expiration Date

    Saturday, July 11, 2020

    Target Audience

    Pharmacist, Pharmacy Technician, Nurse

    Cost

    $0.00

    • Overview

      It is estimated that in the United States approximately 25% of patients infected with HIV are also coinfected with the hepatitis C virus. This percentage increases to 80% in patients with HIV who also inject drugs. Research has shown that HIV accelerates the progression of liver disease in coinfected patients and increases the risk of developing cirrhosis and cirrhosis complications. In the era of direct-acting antivirals the landscape for treating coinfected patients has changed dramatically with cure rates for HCV of great than 90%. Given these advances in treatment it is pertinent for pharmacists, pharmacy technicians and nurses to have a general understanding of the implications of coinfection on disease progression, screening and treatment.

      Rating

         4.25  out of 5

      Handouts

      • Slide Document :   17122H01_4pp.pdf
      • Slide Document :   17122H01_2pp.pdf

      Financial Support By

      Merck & Co., Inc.
    • Pharmacist

      Explain how coinfection impacts HCV disease progression
      Describe the prevalence of HIV/HCV coinfection in the United States
      Given patient cases determine which patients are eligible for treatment using the AASLD/IDSA recommendations

      Pharmacy Technician

      List the modes of transmission for HIV and HCV
      Describe prevention strategies to decrease transmission of HIV and HCV
      Explain who should be tested for HIV and HCV using CDC recommendations

      Nurse

      Explain how coinfection impacts HCV disease progression
      Describe the prevalence of HIV/HCV coinfection in the United States
      Given patient cases determine which patients are eligible for treatment using the AASLD/IDSA recommendations
    • Activity Type

      Knowledge

      CE Broker

      20-576653

      Universal Activity Number

      Pharmacist 0798-0000-17-122-H01-P
      Pharmacy Technician 0798-0000-17-122-H01-T
      Nurse 0798-0000-17-122-H01-P

      ACPE PharmCon is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.

      PharmCon is an approved course provider for continuing education for nurses by the Florida Board of Nursing. PharmCon is also recognized by the California Board of Nursing as a provider of nursing programs.

      In order to obtain a Statement of Credit, participants must score no less than a 70% on the activity's test and complete a program evaluation.


    HARDWARE REQUIREMENTS
    Standard Windows/Mac System
    iPad or iPhone
    Minimum screen resolution: 1024x768
    Speakers or headphones
     


    SOFTWARE REQUIREMENTS
    Microsoft Edge
    Internet Explorer 8.0 or higher
    Google Chrome
    Safari
    Firefox 3.0.3 or higher


    NETWORK REQUIREMENTS
    Broadband Internet Connection:
    T1, Hi-speed DSL or Cable
    4G cellular connection
     
     

    This continuing education activity is held as copyright by PharmCon, Inc. Through this notice, PharmCon, Inc. grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owner(s).